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ABSTRACT  
Background: Activation of the CXCL12/CXCR4 axis is known to stimulate androgen-
independent activation of the androgen receptor (AR) in the LNCaP prostate cancer cell line.  In 
the present study, the CXCL12-stimulated expression profile of androgen responsive genes 
(ARGs) and AR:co-regulator protein:protein interactions has been identified by microarray and 
proteomic analysis, respectively.   
Methods:  To directly identify proteins that interacted with the AR in response to CXCL12 
stimulation, LNCaP cells treated with CXCL12 were subjected to a total proteomics analysis 
after co-immunoprecipitation (co-IP) with anti-AR antibody.  AR- interacting proteins from co-IP 
were pre-fractionated by SDS-PAGE, in-gel trypsin digested, and analyzed by liquid 
chromatography coupled to MS (nanoLC-MS/MS).  Acquired MS2 data was searched using 
MASCOT against a SWISSProt human database.   Detected proteins were analyzed by spectral 
counting to qualitatively determine significant changes in protein expression.  
Results: Gene expression profiling and proteomics analysis of CXCL12-treated LNCaP cells 
indicated a robust regulation of ARGs, including known AR co-regulators and/or AR-interacting 
proteins.  All known AR co-regulators were extracted and segregated according to their 
molecular function.  GTF2 (Transcription factor), ARID1A (Chromatin Remodeling complex 
component) and PRDX1 (other function) are the AR co-regulators which showed greater than  
two fold more interaction with AR in response to CXCL12 treatment, and HNRNPD (Splicing 
and RNA metabolism) is the protein which is commonly differentially regulated in both 
microarray and proteomic analysis in response to CXCL12 treatment.  The potential role of the 
above AR co-regulators in promoting the CXCL12- mediated and androgen-independent AR 
activation and hence the prostate cancer is yet to be elucidated.   
Conclusions: These data shed new light into the role of ARGs and/or AR Co-regulators in 
CXCL12- mediated androgen independent activation of AR and suggests new therapeutic 
targets for the treatment of castration-resistant prostate cancers.  
